Changes in cytokine profile during local IL-2 therapy in cancer patients

被引:0
|
作者
Tomova, R
Pomakov, J
Jacobs, JJL
Adjarov, D
Popova, S
Altankova, I
Den Otter, W
Krastev, Z
机构
[1] Univ Hosp St Ivan Rilski, Gastrointestinal Clin, Sofia 1431, Bulgaria
[2] Univ Hosp St Ivan Rilski, Dept Clin Immunol, Sofia 1431, Bulgaria
[3] Univ Hosp St Ivan Rilski, Dept Clin Lab, Sofia 1431, Bulgaria
[4] Univ Utrecht, Fac Vet Med, Dept Pathobiol, NL-3508 TD Utrecht, Netherlands
关键词
IL-2; therapy; cytokines; IL-5; IL-10;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Exogenous interleukin 2 (IL-2) can influence the complex cytokine network in vivo. This study investigated the cytokine profile of patients with different malignancies before and after local IL-2 administration. Patients and Methods: The human TH1 / TH2 cytometric bead array (CBA) kit was used to investigate IL-2, IFN gamma, TNF alpha. IL-4, IL-5 and IL- 10 in a control group and in 13 patients. Results: The baseline serum IL-4 levels in patients were lower than in healthy controls, while the baseline ascitic IL-10 levels in patients was higher than in serum. The IL-2 applications induced a strong serum increase in IL-2 and IL-5 and even more in ascites, while IL-10 increased weakly and mainly locally. One month after the start of therapy, the serum IFN gamma had increased in patients, reaching the level of the control group. Conclusion: After local injection, IL-2 probably leaks into the blood circulation. The higher increases of IL-2, IL-5 and IL-10 in ascites compared to the serum suggests that the injected cytokines and their effects are mainly local. The minor increase of the immunosuppressive IL-10 could explain the therapeutic difference between local and systemic IL-2 therapy since IL-10 levels markedly increase after systemic IL-2 therapy. IL-5 was always increased after IL-2 therapy and, consequently, may be a downstream mediator of antitumour responses.
引用
收藏
页码:2037 / 2047
页数:11
相关论文
共 50 条
  • [1] Local therapy of cancer with free IL-2
    Willem Den Otter
    John J. L. Jacobs
    Jan J. Battermann
    Gerrit Jan Hordijk
    Zachary Krastev
    Ekaterina V. Moiseeva
    Rachel J. E. Stewart
    Paul G. P. M. Ziekman
    Jan Willem Koten
    Cancer Immunology, Immunotherapy, 2008, 57 : 931 - 950
  • [2] Local therapy of cancer with free IL-2
    Den Otter, Willem
    Jacobs, John J. L.
    Battermann, Jan J.
    Hordijk, Gerrit Jan
    Krastev, Zachary
    Moiseeva, Ekaterina V.
    Stewart, Rachel J. E.
    Ziekman, Paul G. P. M.
    Koten, Jan Willem
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (07) : 931 - 950
  • [3] IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy
    Koten, JW
    Van Luyn, MJA
    Cade, JA
    Brouwer, L
    Hennink, WE
    Bijleveld, C
    Den Otter, W
    CYTOKINE, 2003, 24 (03) : 57 - 66
  • [4] The IL-2 cytokine family in cancer immunotherapy
    Sim, Geok Choo
    Radvanyi, Laszlo
    CYTOKINE & GROWTH FACTOR REVIEWS, 2014, 25 (04) : 377 - 390
  • [5] Cytokine production, IL-2 surface and soluble receptors during IL-2 treatment
    Dmoszynska, A
    Kandefer-Szerszen, M
    Legiec, W
    Rolinski, J
    Kaminska, T
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 82 - 82
  • [6] IL-2 gene therapy of advanced lung cancer patients
    Tan, YY
    Xu, MX
    Wang, WG
    Zhang, FS
    Li, DZ
    Xu, XL
    Gu, JR
    Hoffman, RM
    ANTICANCER RESEARCH, 1996, 16 (4A) : 1993 - 1998
  • [7] IL-2 antibodies in type 1 diabetes and during IL-2 therapy
    Churlaud, Guillaume
    Rosenzwajg, Michelle
    Cacoub, Patrice
    Saadoun, David
    Valteau-Couanet, Dominique
    Chaput, Nathalie
    Pugliese, Alberto
    Klatzmann, David
    DIABETOLOGIA, 2018, 61 (09) : 2066 - 2068
  • [8] IL-2 antibodies in type 1 diabetes and during IL-2 therapy
    Guillaume Churlaud
    Michelle Rosenzwajg
    Patrice Cacoub
    David Saadoun
    Dominique Valteau-Couanet
    Nathalie Chaput
    Alberto Pugliese
    David Klatzmann
    Diabetologia, 2018, 61 : 2066 - 2068
  • [9] Analysis of T(H)1/T(H)2 cytokine gene profile during low dose IL-2 therapy in patients with AIDS or AIDS lymphoma.
    Khatri, VP
    Yu, F
    Baiocchi, RA
    Shah, MH
    Zwerling, BH
    Gould, M
    Bernstein, ZP
    Caligiuri, MA
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 14 (04): : 99 - 99
  • [10] KINETICS AND FUNCTION OF PERITONEAL-EXUDATE CELLS DURING LOCAL IL-2 GENE-THERAPY OF CANCER
    BUBENIK, J
    ZEUTHEN, J
    INDROVA, M
    BUBENIKOVA, D
    SIMOVA, J
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1994, 4 (01) : 13 - 16